A clinical trial suggests that the diabetes drug lixisenatide, related to the latest generation of obesity drugs, may slow the progression of Parkinson’s disease symptoms. Participants who took lixisenatide for 12 months showed no worsening of their symptoms, offering hope for a condition characterized by progressive loss of motor control. This trial marks a significant step in addressing Parkinson’s, with researchers emphasizing the need for further studies to optimize dosing and manage side effects. Lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has shown efficacy in animal studies and smaller human trials, suggesting its potential as a treatment for Parkinson’s.